SCHEMBL2585538

SCHEMBL2585538

CCOc1nccnc1CC

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 1/20 0.44
GRM5 P41594 1/20 0.41
LRRK2 Q5S007 1/20 0.38
SSTR4 P31391 1/20 0.38
NQO1 P15559 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
NPSR1 Q6W5P4 1/20 0.32
NPC1 O15118 2/20 0.32
ALDH1A1 P00352 1/20 0.32
TP53 P04637 1/20 0.32
PKM P14618 1/20 0.32
RAB9A P51151 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
SLC6A2 P23975 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11437617 0.82 SMN1; SMN2 (0.43) SMN1; SMN2HPGDGRM5LRRK2NQO1
SCHEMBL2586207 0.82 SMN1; SMN2 (0.41) SMN1; SMN2HPGDGRM5LRRK2NQO1
SCHEMBL7598688 0.82 HPGD (0.52) SMN1; SMN2HPGDGRM5LRRK2NQO1
SCHEMBL30610260 0.81 CYP2D6 (0.35) SMN1; SMN2HPGDGRM5SSTR4KMT2A
SCHEMBL1607631 0.81 CYP2D6 (0.35) SMN1; SMN2HPGDGRM5SSTR4KMT2A
SCHEMBL31462072 0.80 SMN1; SMN2 (0.40) SMN1; SMN2HPGDGRM5LRRK2NQO1
Ammonia Solution, Strong SCHEMBL28789679 0.79 HPGD (0.50) SMN1; SMN2HPGDGRM5LRRK2NQO1
SCHEMBL2585189 0.79 CYP2D6 (0.39) SMN1; SMN2HPGDGRM5LRRK2KMT2A
SCHEMBL2584656 0.79 HPGD (0.39) SMN1; SMN2HPGDGRM5LRRK2KMT2A
SCHEMBL34472956 0.76 PDE3B (0.39) PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250017954-A1 Formulations and Methods for Treating Symptoms of Menopause Kindra Corporation (US) 2025-01-16 US claimed
EP-4433045-A2 FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE KINDRA CORPORATION (US) 2024-09-25 EP claimed
CN-118510501-A Formulations and methods for treating climacteric symptoms 金卓拉公司 2024-08-16 CN claimed
WO-2023091628-A2 FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) 2023-05-25 WO claimed
US-11504443-B2 Odor-modulating agent and odor-modulating method YAMAMOTO PERFUMERY CO., LTD. (JP) 2022-11-22 US claimed
US-11365370-B2 Fragrance compositions THE PROCTER & GAMBLE COMPANY (US) 2022-06-21 US claimed
CN-111565764-A Odor conversion agent for conversion of odor of asphalt, sludge, sewage, ginkgo biloba, compost, marine animal, vegetable, garbage or coating, and odor conversion method for conversion of odor of asphalt, sludge, sewage, ginkgo biloba, compost, marine animal, vegetable, garbage or coating 山本香料株式会社 2020-08-21 CN claimed
EP-2854750-B1 TRPA1 ANTAGONISTS FOR REDUCING NEGATIVE SENSATIONS CAUSED BY HYDROGEN PEROXIDE PROCTER & GAMBLE (US) 2019-10-02 EP claimed
US-20190175777-A1 ODOR-MODULATING AGENT AND ODOR-MODULATING METHOD YAMAMOTO PERFUMERY CO., LTD. (JP) 2019-06-13 US claimed
EP-3467078-A1 ODOR-MODULATING AGENT AND ODOR-MODULATING METHOD Yamamoto Perfumery Co. Ltd. (JP) 2019-04-10 EP claimed
US-20150322376-A1 Fragrance Compositions THE PROCTER & GAMBLE COMPANY 2015-11-12 US claimed
EP-2931854-A1 FRAGRANCE MATERIALS The Procter & Gamble Company (US) 2015-10-21 EP claimed
EP-2931236-A2 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS The Procter & Gamble Company (US) 2015-10-21 EP claimed
EP-2931234-A2 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS The Procter and Gamble Company (US) 2015-10-21 EP claimed
US-20140179722-A1 Antiperspirant and Deodorant Compositions THE PROCTER & GAMBLE COMPANY (US) 2014-06-26 US claimed
WO-2014093819-A2 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 WO claimed
US-20140170101-A1 Antiperspirant and Deodorant Compositions THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 US claimed
US-20140170194-A1 FRAGRANCE MATERIALS THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 US claimed
WO-2014093807-A1 FRAGRANCE MATERIALS THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 WO claimed
WO-2014093747-A2 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2014-06-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140170101-A1 Antiperspirant and Deodorant Compositions LPO, GPX4, DEK SMN1; SMN2 4196/4885HPGD 291/4885GRM5 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.